Recent Advances in Paclitaxel-based Self-Delivery Nanomedicine for Cancer Therapy
- 1 September 2021
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 28 (31), 6358-6374
- https://doi.org/10.2174/0929867327666201111143725
Abstract
Paclitaxel (PTX) is the first natural plant-derived chemotherapeutic drug approved by the Food and Drug Administration. However, the clinical applications of PTX are limited by some drawbacks, such as poor water solubility, rapid blood clearance, nonspecific distribution, and adverse side effects. Nanocarriers have made important contributions to drug delivery and cancer therapy in recent years. However, low drug loading capacity, nanocarrier excipients-induced toxicity or immunogenicity, and complicated synthesis technologies pose a challenge for the clinical application of nanocarriers. To address these issues, the self-delivery nanomedicine (SDNs), in which pure drug molecules directly self-assemble into nanomedicine, have been developed for drug delivery and enhancing antitumor efficacy. In this review, we comprehensively summarize the recent advances in PTX-based SDNs for cancer therapy. First, the self-assembly strategies to develop pure PTX nanodrugs are discussed. Then, the emerging strategies of co-assembly PTX and other therapeutic agents for effective combination therapy are presented, composing of combination chemotherapy, chemo-photothermal therapy, chemo-photodynamic therapy, chemo-immunotherapy, and chemo-gene therapy. Finally, the limitations and future outlook of SDNs are discussed. The rational design of these unique nanoplatforms may make a new direction to develop highly efficient drug delivery systems for cancer therapy.Keywords
Funding Information
- NIH/NCI Cancer Center Support Grant (P30 CA008748)
- China Postdoctoral Science Foundation (2019M653660)
- Fundamental Research Funds for the Central Universities (xzy012019077)
- Nantong Municipal Science and Technology Project (MS12018098)
- National Natural Science Foundation of China (51903201)
This publication has 93 references indexed in Scilit:
- Paclitaxel–Paclitaxel Prodrug Nanoassembly as a Versatile Nanoplatform for Combinational Cancer TherapyACS Applied Materials & Interfaces, 2016
- Recent advances in drug delivery strategies for improved therapeutic efficacy of gemcitabineEuropean Journal of Pharmaceutical Sciences, 2016
- Carrier-Free, Chemophotodynamic Dual Nanodrugs via Self-Assembly for Synergistic Antitumor TherapyACS Applied Materials & Interfaces, 2016
- Synthetic Self‐Assembled Materials in Biological EnvironmentsAdvanced Materials, 2016
- A Near Infrared Light Triggered Hydrogenated Black TiO2 for Cancer Photothermal TherapyAdvanced Healthcare Materials, 2015
- Preparation and Size Control of Sub-100 nm Pure NanodrugsNano Letters, 2014
- Combination of Small Molecule Prodrug and Nanodrug Delivery: Amphiphilic Drug–Drug Conjugate for Cancer TherapyJournal of the American Chemical Society, 2014
- Carrier-free functionalized multidrug nanorods for synergistic cancer therapyBiomaterials, 2013
- Mitochondria‐Targeting Single‐Walled Carbon Nanotubes for Cancer Photothermal TherapySmall, 2011
- Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicityOncogene, 2001